A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Carfilzomib (KYPROLIS)

Proteasome Inhibitor class · 1 generic manufacturer · 1 ANDAs filed at FDA.

First FDA approval2012-07-20
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$30.3M in CY2024 Part D spend3K claims · 423 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Carfilzomib used for?

Carfilzomib is a Proteasome Inhibitor medication tracked in Medicare Part D.

Is there a generic for Carfilzomib?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Carfilzomib?

NADAC pricing data not currently available for this drug.

Is Carfilzomib on the FDA shortage list?

No. Carfilzomib is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Proteasome Inhibitor1 alternative in D1
01
Bortezomib
Brand: BORUZU
Lowest NADAC
17Generic mfrs
$5.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.